Clinical effect of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome
10.3760/cma.j.issn.1008-6706.2020.06.020
- VernacularTitle:脂必泰胶囊治疗老年人痰浊血瘀型高脂血症的疗效观察
- Author:
Yuanyuan CHEN
1
;
Qingsheng LIU
;
Qilan CHEN
;
Jia ZHOU
Author Information
1. 杭州市中医院 浙江中医药大学附属广兴医院老年病科 310007
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(6):733-737
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome.Methods:From June 2014 to June 2015, 126 elderly patients with primary hyperlipidemia of phlegm and blood stasis syndrome admitted to Hangzhou Hospital of Traditional Chinese Medicine were randomly divided into control group and observation group, with 63 cases in each group.The patients in the control group were given basic treatment plus atorvastatin calcium tablets, and the patients in the observation group were treated with Zhibitai capsule on the basis of the control study.Both two groups received continuous treatment for 12 weeks.The clinical efficacy, TCM syndrome integral, blood lipid, hemorheology and adverse reactions of the two groups were observed.Results:The total effective rate in the observation group was 92.1%(58/63), which was higher than 81.0%(51/63) in the control group, and the difference was statistically significant(χ 2=8.199, P<0.05). After treatment, the TCM syndrome score of the observation group was (9.31±1.78)points, which was lower than that of the control group[(15.88±2.35)points], and the difference was statistically significant( t=17.689, P<0.05). After treatment, the levels of total plasma cholesterol, triglyceride, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the observation group were (5.16±0.28)mmol/L, (1.89±0.21)mmol/L, (3.34±0.11)mmol/L and (1.18±0.13)mmol/L, respectively, which in the control group were (5.31±0.15)mmol/L, (2.22±0.20)mmol/L, (3.47±0.16)mmol/L and (1.11±0.12)mmol/L, respectively, the differences between the two groups were statistically significant( t=3.748, 9.032, 5.314, 3.140, all P<0.05). After treatment, the whole blood low shear viscosity, high shear viscosity, plasma viscosity and fibrinogen in the observation group were (10.68±2.38)mPa/s, (4.11±0.31)mPa/s, (1.33±0.22)mPa/s, (3.01±0.22)g/L, respectively, which in the control group were (11.55±2.39)mPa/s, (4.43±0.30)mPa/s, (1.61±0.25)mPa/s, (3.25±0.22)g/L, respectively, the differences between the two groups were statistically significant( t=2.047, 5.888, 6.674, 6.123, all P<0.05). There was no statistically significant difference in the adverse reactions between the two groups( P>0.05). Conclusion:Zhibitai capsule can effectively improve the clinical efficacy, improve TCM syndromes, reduce blood lipids and improve hemorheology parameters in elderly patients with hyperlipidemia syndrome of phlegm and blood stasis syndrome, with no obvious adverse reactions, which is worthy of clinical promotion.
